ACET: Adicet Bio, Inc.
About
Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of “off-the-shelf” gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.
Current Value
$0.911 Year Return
Current Value
$0.911 Year Return
Key Details
Market Cap
$75.31M
P/E Ratio
-0.54
1Y Stock Return
-20.52%
1Y Revenue Growth
-100.00%
Dividend Yield
0.00%
Price to Book
0.4
Strategies that include ACET
Stock's related to ACET
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ACCD | 43.55% | $298.79M | -53.45% | 0.00% |
| JNPR | 42.04% | $11.73B | +31.03% | 2.48% |
| PRTA | 40.49% | $777.00M | -55.88% | 0.00% |
| KYMR | 39.24% | $2.82B | +120.42% | 0.00% |
| CTLT | 35.38% | $10.83B | +50.66% | 0.00% |
| PTGX | 33.39% | $2.48B | +147.47% | 0.00% |
| FATE | 33.12% | $235.76M | -13.39% | 0.00% |
| MRSN | 32.02% | $244.60M | +32.44% | 0.00% |
| AXSM | 31.59% | $4.76B | +63.38% | 0.00% |
| PRCT | 30.13% | $5.14B | +172.19% | 0.00% |
| ATXS | 30.07% | $527.10M | +110.36% | 0.00% |
| MITT | 29.62% | $196.54M | +28.82% | 9.85% |
| ARCT | 29.05% | $462.38M | -27.45% | 0.00% |
| CATX | 28.81% | $202.76M | +17.65% | 0.00% |
| SRPT | 28.50% | $10.55B | +31.91% | 0.00% |
| DVAX | 28.23% | $1.62B | -8.31% | 0.00% |
| GBIO | 28.16% | $88.17M | +14.78% | 0.00% |
| PRAX | 27.95% | $1.36B | +331.03% | 0.00% |
| KRUS | 26.68% | $1.14B | +52.99% | 0.00% |
| DOC | 26.59% | $15.18B | +30.55% | 5.50% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| IMXI | 0.07% | $659.29M | -0.28% | 0.00% |
| ESGR | 0.07% | $4.94B | +21.60% | 0.00% |
| GOGL | -0.13% | $2.24B | +27.01% | 9.09% |
| ATUS | 0.13% | $1.19B | +12.61% | 0.00% |
| FENG | -0.18% | $13.53M | +94.49% | 0.00% |
| MVO | 0.18% | $105.11M | -23.39% | 16.89% |
| CLF | 0.19% | $5.87B | -29.50% | 0.00% |
| CHRW | -0.19% | $12.83B | +31.18% | 2.26% |
| SEAT | 0.21% | $474.79M | -55.10% | 0.00% |
| UEIC | 0.24% | $152.04M | +56.02% | 0.00% |
| PSN | 0.27% | $10.55B | +57.16% | 0.00% |
| MUR | -0.31% | $4.83B | -21.94% | 3.62% |
| RYAN | -0.34% | $8.98B | +57.73% | 0.61% |
| GPRK | -0.35% | $423.11M | -12.86% | 8.50% |
| INFN | -0.36% | $1.57B | +57.01% | 0.00% |
| GRPN | -0.41% | $365.86M | -8.73% | 0.00% |
| TLYS | -0.42% | $113.97M | -55.11% | 0.00% |
| GEO | 0.42% | $4.02B | +193.76% | 0.00% |
| WRB | -0.45% | $23.68B | +34.33% | 0.68% |
| LMT | 0.47% | $128.48B | +20.34% | 2.32% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PULM | -17.28% | $22.32M | +230.27% | 0.00% |
| CME | -11.67% | $81.64B | +7.34% | 2.00% |
| RDDT | -11.53% | $27.74B | +364.76% | 0.00% |
| WHLM | -10.51% | $19.81M | -14.82% | 0.00% |
| TEM | -9.66% | $8.26B | 0.00% | 0.00% |
| CBOE | -8.76% | $22.09B | +17.17% | 1.08% |
| LPLA | -8.20% | $24.20B | +42.81% | 0.37% |
| TEO | -8.17% | $1.61B | +73.88% | 0.00% |
| CRTO | -7.95% | $2.12B | +57.48% | 0.00% |
| LRN | -7.71% | $4.51B | +75.87% | 0.00% |
| KNTK | -7.27% | $3.71B | +73.04% | 4.86% |
| SOLV | -7.14% | $12.03B | -12.96% | 0.00% |
| HUSA | -6.83% | $18.58M | -19.77% | 0.00% |
| ASPS | -6.47% | $20.33M | -82.43% | 0.00% |
| VIRT | -6.43% | $3.25B | +113.85% | 2.55% |
| UUU | -6.10% | $4.98M | -18.37% | 0.00% |
| PGR | -5.96% | $154.33B | +62.01% | 0.44% |
| EOG | -5.71% | $76.21B | +11.42% | 2.68% |
| MNR | -5.29% | $1.70B | -6.89% | 15.55% |
| NARI | -5.13% | $2.91B | -15.78% | 0.00% |
ETF's related to ACET
News
Yahoo
REDWOOD CITY, Calif. & BOSTON, November 18, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the opening of enrollment for the Phase 1 clinical trial evaluating ADI-270 in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC).
Finnhub
Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma First gamma delta CAR T cell therapy with the potential to address...
Yahoo
REDWOOD CITY, Calif. & BOSTON, November 18, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the first LN patient has been dosed in the Phase 1 clinical trial evaluating ADI-001 in autoimmune diseases.
Yahoo
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Finnhub
REDWOOD CITY, BOSTON - Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic, gamma delta T cell therapies for autoimmune diseases and cancer, today announced...
Yahoo
REDWOOD CITY, Calif. & BOSTON, November 16, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic, gamma delta T cell therapies for autoimmune diseases and cancer, today announced that clinical biomarker data from the ADI-001 Phase 1 GLEAN trial which demonstrates robust tissue homing, significant CAR T cell activation, and complete CD19+ B cell depletion in secondary lymphoid tissue will be featured in an oral session at ACR Converge
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.